PDF(Pubmed)
Abstract：
UNASSIGNED: Angiotensin-converting enzyme 2 (ACE2) played an important role in the renin-angiotensin-aldosterone system (RAAS) and it was proved to be renoprotective in renal disease. Urinary angiotensin-converting enzyme 2 (uACE2) has been shown to reflect renal injury in human and experimental studies, but its role in feline kidney disease remains unknown.
UNASSIGNED: Our objectives involve comparing uACE2 concentrations and activities in cats across CKD stages with healthy controls, investigating the relationship between uACE2 concentrations, activities, and clinicopathological data in feline CKD patients, and assessing the predictive abilities of both for CKD progression.
UNASSIGNED: A retrospective, case-control study. The concentration and activity of uACE2 were measured by commercial ELISA and fluorometric assay kits, respectively. The concentration was adjusted to give uACE2 concentration-to-creatinine ratios (UACCRs).
UNASSIGNED: In total, 67 cats consisting of 24 control and 43 chronic kidney disease (CKD), including 24 early-stage CKD and 19 late-stage CKD, were enrolled in this study. UACCR values were significantly higher in both early-stage (2.100 [1.142-4.242] x 10-6) and late-stage feline CKD (4.343 [2.992-5.0.71] x 10-6) compared to healthy controls (0.894 [0.610-1.076] x 10-6; p < 0.001), and there was also significant difference between-early stage group and late-stage group (p = 0.026). Urinary ACE2 activity (UAA) was significantly lower in CKD cats (1.338 [0.644-2.755] x pmol/min/ml) compared to the healthy cats (7.989 [3.711-15.903] x pmol/min/ml; p < 0.001). UACCR demonstrated an independent, positive correlation with BUN (p < 0.001), and UAA exhibited an independent, negative correlation with plasma creatinine (p < 0.001). Both UACCR and UAA did not yield significant results in predicting CKD progression based on the ROC curve analysis.
UNASSIGNED: uACE2 concentration and activity exhibit varying changes as renal function declines, particularly in advanced CKD cats.
UNASSIGNED: Our objectives involve comparing uACE2 concentrations and activities in cats across CKD stages with healthy controls, investigating the relationship between uACE2 concentrations, activities, and clinicopathological data in feline CKD patients, and assessing the predictive abilities of both for CKD progression.
UNASSIGNED: A retrospective, case-control study. The concentration and activity of uACE2 were measured by commercial ELISA and fluorometric assay kits, respectively. The concentration was adjusted to give uACE2 concentration-to-creatinine ratios (UACCRs).
UNASSIGNED: In total, 67 cats consisting of 24 control and 43 chronic kidney disease (CKD), including 24 early-stage CKD and 19 late-stage CKD, were enrolled in this study. UACCR values were significantly higher in both early-stage (2.100 [1.142-4.242] x 10-6) and late-stage feline CKD (4.343 [2.992-5.0.71] x 10-6) compared to healthy controls (0.894 [0.610-1.076] x 10-6; p < 0.001), and there was also significant difference between-early stage group and late-stage group (p = 0.026). Urinary ACE2 activity (UAA) was significantly lower in CKD cats (1.338 [0.644-2.755] x pmol/min/ml) compared to the healthy cats (7.989 [3.711-15.903] x pmol/min/ml; p < 0.001). UACCR demonstrated an independent, positive correlation with BUN (p < 0.001), and UAA exhibited an independent, negative correlation with plasma creatinine (p < 0.001). Both UACCR and UAA did not yield significant results in predicting CKD progression based on the ROC curve analysis.
UNASSIGNED: uACE2 concentration and activity exhibit varying changes as renal function declines, particularly in advanced CKD cats.
摘要：
■血管紧张素转换酶2（ACE2）在肾素-血管紧张素-醛固酮系统（RAAS）中起重要作用，被证明对肾脏疾病具有肾脏保护作用。尿血管紧张素转换酶2（uACE2）在人体和实验研究中已被证明可以反映肾损伤，但其在猫肾病中的作用尚不清楚。
■我们的目标涉及比较猫在CKD阶段的uACE2浓度和活动与健康对照，调查uACE2浓度之间的关系，活动,猫CKD患者的临床病理数据，并评估两者对CKD进展的预测能力。
■回顾，病例对照研究。uACE2的浓度和活性通过商业ELISA和荧光测定试剂盒进行测量，分别。调节浓度以得到uACE2浓度-肌酸酐比率(UACCRs)。
■总共，67只猫，包括24只对照和43只慢性肾病（CKD），包括24例早期CKD和19例晚期CKD，参加了这项研究。与健康对照组（0.894[0.610-1.076]x10-6;p<0.001）相比，早期阶段（2.100[1.142-4.242]x10-6）和晚期阶段猫科动物CKD（4.343[2.992-5.0.71]x10-6）的UACCR值明显更高，早期组和晚期组之间也存在显着差异（p=0.026）。与健康猫相比，CKD猫的尿ACE2活性（UAA）显着降低（1.338[0.644-2.755]xpmol/min/ml）（7.989[3.711-15.903]xpmol/min/ml；p<0.001）。UACCR展示了一个独立的，与BUN呈正相关(p<0.001)，UAA展示了一个独立的，与血浆肌酐呈负相关(p<0.001)。UACCR和UAA在基于ROC曲线分析预测CKD进展方面均未产生显著结果。
■uACE2浓度和活性随着肾功能下降而表现出不同的变化，特别是在先进的CKD猫。
■我们的目标涉及比较猫在CKD阶段的uACE2浓度和活动与健康对照，调查uACE2浓度之间的关系，活动,猫CKD患者的临床病理数据，并评估两者对CKD进展的预测能力。
■回顾，病例对照研究。uACE2的浓度和活性通过商业ELISA和荧光测定试剂盒进行测量，分别。调节浓度以得到uACE2浓度-肌酸酐比率(UACCRs)。
■总共，67只猫，包括24只对照和43只慢性肾病（CKD），包括24例早期CKD和19例晚期CKD，参加了这项研究。与健康对照组（0.894[0.610-1.076]x10-6;p<0.001）相比，早期阶段（2.100[1.142-4.242]x10-6）和晚期阶段猫科动物CKD（4.343[2.992-5.0.71]x10-6）的UACCR值明显更高，早期组和晚期组之间也存在显着差异（p=0.026）。与健康猫相比，CKD猫的尿ACE2活性（UAA）显着降低（1.338[0.644-2.755]xpmol/min/ml）（7.989[3.711-15.903]xpmol/min/ml；p<0.001）。UACCR展示了一个独立的，与BUN呈正相关(p<0.001)，UAA展示了一个独立的，与血浆肌酐呈负相关(p<0.001)。UACCR和UAA在基于ROC曲线分析预测CKD进展方面均未产生显著结果。
■uACE2浓度和活性随着肾功能下降而表现出不同的变化，特别是在先进的CKD猫。
